111 related articles for article (PubMed ID: 8891165)
1. Prophylactic treatment of cytomegalovirus infection with traditional herbs.
Yukawa TA; Kurokawa M; Sato H; Yoshida Y; Kageyama S; Hasegawa T; Namba T; Imakita M; Hozumi T; Shiraki K
Antiviral Res; 1996 Oct; 32(2):63-70. PubMed ID: 8891165
[TBL] [Abstract][Full Text] [Related]
2. [Cytomegalovirus infection and its possible treatment with herbal medicines].
Shiraki K; Yukawa T; Kurokawa M; Kageyama S
Nihon Rinsho; 1998 Jan; 56(1):156-60. PubMed ID: 9465682
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of traditional herbal medicines in combination with acyclovir against herpes simplex virus type 1 infection in vitro and in vivo.
Kurokawa M; Nagasaka K; Hirabayashi T; Uyama S; Sato H; Kageyama T; Kadota S; Ohyama H; Hozumi T; Namba T
Antiviral Res; 1995 May; 27(1-2):19-37. PubMed ID: 7486956
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections.
Hostetler KY; Rybak RJ; Beadle JR; Gardner MF; Aldern KA; Wright KN; Kern ER
Antivir Chem Chemother; 2001 Jan; 12(1):61-70. PubMed ID: 11437323
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice.
Cook CH; Zhang Y; Sedmak DD; Martin LC; Jewell S; Ferguson RM
Crit Care Med; 2006 Mar; 34(3):842-9. PubMed ID: 16521279
[TBL] [Abstract][Full Text] [Related]
6. Adoptive transfer of cytomegalovirus-specific effector CD4+ T cells provides antiviral protection from murine CMV infection.
Jeitziner SM; Walton SM; Torti N; Oxenius A
Eur J Immunol; 2013 Nov; 43(11):2886-95. PubMed ID: 23921569
[TBL] [Abstract][Full Text] [Related]
7. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS.
De Castro LM; Kern ER; De Clercq E; Ghaffar A; Mayer EP; Vogt PE; Gangemi JD
Antiviral Res; 1991 Jul; 16(1):101-14. PubMed ID: 1663726
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of murine cytomegalovirus lung infection and interstitial pneumonitis by acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine.
Shanley JD; Morningstar J; Jordan MC
Antimicrob Agents Chemother; 1985 Aug; 28(2):172-5. PubMed ID: 3010835
[TBL] [Abstract][Full Text] [Related]
9. Murine model for immunoprophylaxis of cytomegalovirus infection. I. Efficacy of immunization.
Minamishima Y; Eizuru Y; Yoshida A; Fukunishi R
Microbiol Immunol; 1978; 22(11):693-700. PubMed ID: 85239
[TBL] [Abstract][Full Text] [Related]
10. Aerosol administration of antiviral agents to treat lung infection due to murine cytomegalovirus.
Debs RJ; Montgomery AB; Brunette EN; DeBruin M; Shanley JD
J Infect Dis; 1988 Feb; 157(2):327-31. PubMed ID: 2826613
[TBL] [Abstract][Full Text] [Related]
11. Reduced mortality in murine cytomegalovirus infected mice following prophylactic murine interferon-gamma treatment.
Fennie EH; Lie YS; Low MA; Gribling P; Anderson KP
Antiviral Res; 1988 Nov; 10(1-3):27-39. PubMed ID: 2852918
[TBL] [Abstract][Full Text] [Related]
12. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
13. Anti-HSV-2 activity of Terminalia chebula Retz extract and its constituents, chebulagic and chebulinic acids.
Kesharwani A; Polachira SK; Nair R; Agarwal A; Mishra NN; Gupta SK
BMC Complement Altern Med; 2017 Feb; 17(1):110. PubMed ID: 28196487
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of natural killer cell activity induced by cytomegalovirus infection in mice treated with FK506.
Kageyama S; Matsui S; Hasegawa T; Yoshida Y; Sato H; Yamamura J; Kurokawa M; Yamamoto H; Shiraki K
Acta Virol; 1997 Aug; 41(4):215-20. PubMed ID: 9391652
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice.
Yang H; Drain RL; Franco CA; Clark JM
Antiviral Res; 1996 Mar; 29(2-3):233-41. PubMed ID: 8739602
[TBL] [Abstract][Full Text] [Related]
16. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
Ormrod D; Scott LJ; Perry CM
Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
[TBL] [Abstract][Full Text] [Related]
17. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
[TBL] [Abstract][Full Text] [Related]
18. Purification and characterization of eugeniin as an anti-herpesvirus compound from Geum japonicum and Syzygium aromaticum.
Kurokawa M; Hozumi T; Basnet P; Nakano M; Kadota S; Namba T; Kawana T; Shiraki K
J Pharmacol Exp Ther; 1998 Feb; 284(2):728-35. PubMed ID: 9454821
[TBL] [Abstract][Full Text] [Related]
19. Immunoprophylaxis of experimental cytomegalovirus infection.
Minamishima Y
Ann Microbiol (Paris); 1977 Oct; 128(3):399-407. PubMed ID: 203216
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and therapy of cytomegalovirus (CMV)-associated lung disease following anti-CD3 monoclonal antibody treatment in mice with persistent murine CMV in the salivary glands.
Tanaka K; Koga Y; Kimura G; Nomoto K
Transplant Proc; 1995 Feb; 27(1):499-500. PubMed ID: 7879076
[No Abstract] [Full Text] [Related]
[Next] [New Search]
